Summing these studies, it can be concluded that the re-expression of ERα in ER-negative breast cancer cells by inhibiting EGFR or Her-2 signalling restores, at least in part, a hormone-responsiveness and could be useful as a potential therapeutic approach to endocrine-resistant breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.